MEDINDIA
English
हिन्दी
Español
français
中文
Email
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide.
Acebutolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.
Aceclofenac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aceclofenac.
Acemetacin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acemetacin.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide.
Acetyl salicylate
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetylsalicylic acid.
Acetyldigitoxin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin.
Aclidinium
The serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.
Adapalene
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Adapalene.
Albuterol
Salbutamol may increase the hypokalemic activities of Methyclothiazide.
Alclometasone
Alclometasone may increase the hypokalemic activities of Methyclothiazide.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.
Aldosterone
Aldosterone may increase the hypokalemic activities of Methyclothiazide.
Alfacalcidol
The risk or severity of hyperkalemia can be increased when Alfacalcidol is combined with Methyclothiazide.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Methyclothiazide.
Aliskiren
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren.
Allopurinol
The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide.
Alminoprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alminoprofen.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.
Alphaprodine
The risk or severity of adverse effects can be increased when Alphaprodine is combined with Methyclothiazide.
Amcinonide
Amcinonide may increase the hypokalemic activities of Methyclothiazide.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Methyclothiazide.
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Methyclothiazide.
Amiloride
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Methyclothiazide.
Amlodipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.
Amobarbital
Amobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyclothiazide.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyclothiazide.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amyl Nitrite.
Androstenedione
Androstenedione may increase the hypokalemic activities of Methyclothiazide.
Antipyrine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.
Apazone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyclothiazide.
Apraclonidine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apraclonidine.
Apremilast
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Apremilast.
Arbutamine
Arbutamine may increase the hypokalemic activities of Methyclothiazide.
Arformoterol
Arformoterol may increase the hypokalemic activities of Methyclothiazide.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Methyclothiazide.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methyclothiazide.
Aspirin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acetylsalicylic acid.
Atenolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol.
Atracurium
The serum concentration of Methyclothiazide can be increased when it is combined with Atracurium.
Atracurium Besylate
The serum concentration of Methyclothiazide can be increased when it is combined with Atracurium besylate.
Atropine
The serum concentration of Methyclothiazide can be increased when it is combined with Atropine.
Azelastine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azelastine.
Azilsartan
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.
Balsalazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Balsalazide.
Bambuterol
Bambuterol may increase the hypokalemic activities of Methyclothiazide.
Barbexaclone
Barbexaclone may increase the orthostatic hypotensive activities of Methyclothiazide.
Barbital
Barbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Beclomethasone Dipropionate
Beclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.
Benactyzine
The serum concentration of Methyclothiazide can be increased when it is combined with Benactyzine.
Benazepril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bendroflumethiazide.
Benztropine
The serum concentration of Methyclothiazide can be increased when it is combined with Benzatropine.
Benzydamine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Benzydamine.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Methyclothiazide.
Betamethasone
Betamethasone may increase the hypokalemic activities of Methyclothiazide.
Betaxolol
The risk or severity of adverse effects can be increased when Betaxolol is combined with Methyclothiazide.
Biperiden
The serum concentration of Methyclothiazide can be increased when it is combined with Biperiden.
Bisoprolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Methyclothiazide.
Bretylium
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bretylium.
Brimonidine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.
Bromfenac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Methyclothiazide.
Budesonide
Budesonide may increase the hypokalemic activities of Methyclothiazide.
Bufexamac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bufexamac.
Bumetanide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methyclothiazide.
Buprenorphine
The risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Methyclothiazide.
Butylscopolamine
The serum concentration of Methyclothiazide can be increased when it is combined with Butylscopolamine.
Calcifediol
The risk or severity of hyperkalemia can be increased when Calcidiol is combined with Methyclothiazide.
Calcifediol Anhydrous
The risk or severity of hyperkalemia can be increased when Calcidiol is combined with Methyclothiazide.
Calcipotriene
The risk or severity of hyperkalemia can be increased when Calcipotriol is combined with Methyclothiazide.
Calcitriol
The risk or severity of hyperkalemia can be increased when Calcitriol is combined with Methyclothiazide.
Calcium Acetate
Methyclothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.
Calcium Chloride
Methyclothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.
Calcium Chloride Anhydrous
Methyclothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.
Calcium Citrate
Methyclothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.
Calcium Glubionate
Methyclothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.
Calcium gluceptate
Methyclothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.
Calcium Gluconate
Methyclothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.
Calcium Lactate
Methyclothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
Candesartan Cilexetil
The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Methyclothiazide.
Captopril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Captopril.
Carbamazepine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.
Carprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Carprofen.
Carteolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.
Carvedilol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carvedilol.
Casein Allergenic Extract
Methyclothiazide may decrease the excretion rate of Casein which could result in a higher serum level.
Celecoxib
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.
Celiprolol
Celiprolol may increase the hypokalemic activities of Methyclothiazide.
Chloroquine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine.
Chlorothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.
Chlorphenoxamine
The serum concentration of Methyclothiazide can be increased when it is combined with Chlorphenoxamine.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methyclothiazide.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methyclothiazide.
Chlorthalidone
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorthalidone.
Cholecalciferol
The risk or severity of hyperkalemia can be increased when Cholecalciferol is combined with Methyclothiazide.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Choline magnesium trisalicylate.
Ciclesonide
Ciclesonide may increase the hypokalemic activities of Methyclothiazide.
Cilazapril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Cilazapril.
Citalopram
Citalopram may increase the hyponatremic activities of Methyclothiazide.
Clenbuterol
Clenbuterol may increase the hypokalemic activities of Methyclothiazide.
Clevidipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.
Clobetasol
Clobetasol may increase the hypokalemic activities of Methyclothiazide.
Clobetasol Propionate
Clobetasol propionate may increase the hypokalemic activities of Methyclothiazide.
Clobetasone
Clobetasone may increase the hypokalemic activities of Methyclothiazide.
Clocortolone
Clocortolone may increase the hypokalemic activities of Methyclothiazide.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Methyclothiazide.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Methyclothiazide.
Clonidine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.
Clonixin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Clonixin.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Methyclothiazide.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.
Colesevelam
Colesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Methyclothiazide.
Cortisone Acetate
Cortisone acetate may increase the hypokalemic activities of Methyclothiazide.
Curcumin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Curcumin.
Cyclopentolate
The serum concentration of Methyclothiazide can be increased when it is combined with Cyclopentolate.
Cyclophosphamide
The risk or severity of severe leukopenia can be increased when Methyclothiazide is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of severe leukopenia can be increased when Methyclothiazide is combined with Cyclophosphamide.
Dapagliflozin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.
Darifenacin
The serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin.
Deflazacort
Deflazacort may increase the hypokalemic activities of Methyclothiazide.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Methyclothiazide.
Deslanoside
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.
Desloratadine
The serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.
Desonide
Desonide may increase the hypokalemic activities of Methyclothiazide.
Desoximetasone
Desoximetasone may increase the hypokalemic activities of Methyclothiazide.
Desoxycorticosterone acetate
Desoxycorticosterone acetate may increase the hypokalemic activities of Methyclothiazide.
Desoxycorticosterone Pivalate
Desoxycorticosterone Pivalate may increase the hypokalemic activities of Methyclothiazide.
Desvenlafaxine
Desvenlafaxine may increase the hyponatremic activities of Methyclothiazide.
Dexamethasone
Dexamethasone may increase the hypokalemic activities of Methyclothiazide.
Dexetimide
The serum concentration of Methyclothiazide can be increased when it is combined with Dexetimide.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Methyclothiazide.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Dextromoramide is combined with Methyclothiazide.
Dezocine
The risk or severity of adverse effects can be increased when Dezocine is combined with Methyclothiazide.
Diazoxide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diazoxide.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide.
Diclofenac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diclofenac.
Dicyclomine
The serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.
Diflorasone
Diflorasone may increase the hypokalemic activities of Methyclothiazide.
Diflucortolone
Difluocortolone may increase the hypokalemic activities of Methyclothiazide.
Diflunisal
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.
Difluprednate
Difluprednate may increase the hypokalemic activities of Methyclothiazide.
Digitoxin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin.
Digoxin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.
Dihydrotachysterol
The risk or severity of hyperkalemia can be increased when Dihydrotachysterol is combined with Methyclothiazide.
Diltiazem
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diltiazem.
Dinutuximab
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methyclothiazide.
Dipivefrin
Dipivefrin may increase the hypokalemic activities of Methyclothiazide.
Dipyridamole
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.
Dipyrone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.
Dobutamine
Dobutamine may increase the hypokalemic activities of Methyclothiazide.
Dofetilide
Methyclothiazide may increase the QTc-prolonging activities of Dofetilide.
Doxazosin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.
Doxercalciferol
The risk or severity of hyperkalemia can be increased when Doxercalciferol is combined with Methyclothiazide.
Droxicam
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Droxicam.
Droxidopa
Droxidopa may increase the hypokalemic activities of Methyclothiazide.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methyclothiazide.
Duloxetine
Methyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methyclothiazide.
Enalapril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Enalapril.
Enalaprilat
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Enalaprilat.
Epinephrine
Epinephrine may increase the hypokalemic activities of Methyclothiazide.
Eplerenone
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eplerenone.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Methyclothiazide.
Eprosartan
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.
Ergocalciferol
The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Methyclothiazide.
Escitalopram
Escitalopram may increase the hyponatremic activities of Methyclothiazide.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Methyclothiazide.
Estrone
Estrone may increase the hypokalemic activities of Methyclothiazide.
Etanercept
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.
Ethacrynate
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.
Ethanol
Ethanol may increase the orthostatic hypotensive activities of Methyclothiazide.
Ethylmorphine
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methyclothiazide.
Etodolac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.
Etofenamate
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etofenamate.
Etoricoxib
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etoricoxib.
Evening primrose oil
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Evening primrose oil.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Methyclothiazide.
Felbinac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Felbinac.
Felodipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.
Fenbufen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Methyclothiazide.
Fenoprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.
Fenoterol
Fenoterol may increase the hypokalemic activities of Methyclothiazide.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Methyclothiazide.
Ferulic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ferulic acid.
Fesoterodine
The serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.
Floctafenine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Floctafenine.
Fludrocortisone
Fludrocortisone may increase the hypokalemic activities of Methyclothiazide.
Flumethasone
Flumethasone may increase the hypokalemic activities of Methyclothiazide.
Flunisolide
Flunisolide may increase the hypokalemic activities of Methyclothiazide.
Flunisolide Anhydrous (obsolete)
Flunisolide may increase the hypokalemic activities of Methyclothiazide.
Fluocinolone Acetonide
Fluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.
Fluocinonide
Fluocinonide may increase the hypokalemic activities of Methyclothiazide.
Fluocortolone
Fluocortolone may increase the hypokalemic activities of Methyclothiazide.
Fluorometholone
Fluorometholone may increase the hypokalemic activities of Methyclothiazide.
Fluoxetine
Fluoxetine may increase the hyponatremic activities of Methyclothiazide.
FLUPREDNIDENE
Fluprednidene may increase the hypokalemic activities of Methyclothiazide.
Fluprednisolone
Fluprednisolone may increase the hypokalemic activities of Methyclothiazide.
Flurandrenolide
Flurandrenolide may increase the hypokalemic activities of Methyclothiazide.
Flurbiprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone Furoate
Fluticasone furoate may increase the hypokalemic activities of Methyclothiazide.
Fluticasone propionate
Fluticasone propionate may increase the hypokalemic activities of Methyclothiazide.
Fluvoxamine
Fluvoxamine may increase the hyponatremic activities of Methyclothiazide.
Formestane
Formestane may increase the hypokalemic activities of Methyclothiazide.
Formoterol
Formoterol may increase the hypokalemic activities of Methyclothiazide.
Fosinopril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Fosinopril.
Furosemide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.
Gallamine Triethiodide
The serum concentration of Methyclothiazide can be increased when it is combined with Gallamine Triethiodide.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Methyclothiazide.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Methyclothiazide.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Methyclothiazide.
Glycopyrronium
The serum concentration of Methyclothiazide can be increased when it is combined with Glycopyrronium.
Guanfacine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.
Halcinonide
Halcinonide may increase the hypokalemic activities of Methyclothiazide.
Halobetasol
Ulobetasol may increase the hypokalemic activities of Methyclothiazide.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Methyclothiazide.
Heroin
The risk or severity of adverse effects can be increased when Heroin is combined with Methyclothiazide.
Hexobarbital
Hexobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Homatropine
The serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.
Hydralazine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.
Hydrocodone
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.
Hydrocortisone
Hydrocortisone may increase the hypokalemic activities of Methyclothiazide.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Methyclothiazide.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.
Hyoscyamine
The serum concentration of Methyclothiazide can be increased when it is combined with Hyoscyamine.
Ibuprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.
Icatibant
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Icatibant.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Methyclothiazide.
Imidapril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Methyclothiazide.
Indacaterol
Indacaterol may increase the hypokalemic activities of Methyclothiazide.
Indapamide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.
Indobufen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indobufen.
Indomethacin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.
Indoramin
The risk or severity of adverse effects can be increased when Indoramin is combined with Methyclothiazide.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methyclothiazide.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methyclothiazide.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methyclothiazide.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methyclothiazide.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methyclothiazide.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methyclothiazide.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.
Ipratropium Bromide
The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.
Ipratropium Bromide Anhydrous
The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.
Irbesartan
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyclothiazide.
Isoetharine
Isoetarine may increase the hypokalemic activities of Methyclothiazide.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Methyclothiazide.
Isoproterenol
Isoprenaline may increase the hypokalemic activities of Methyclothiazide.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isoxsuprine.
Isradipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isradipine.
Ivabradine
Methyclothiazide may increase the arrhythmogenic activities of Ivabradine.
Kebuzone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Kebuzone.
Ketoprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen.
Ketorolac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.
Labetalol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.
Lacidipine
Methyclothiazide may increase the hypotensive activities of Lacidipine.
Leflunomide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Leflunomide.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Methyclothiazide.
Levalbuterol
Levosalbutamol may increase the hypokalemic activities of Methyclothiazide.
Levobunolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methyclothiazide.
Levodopa
Methyclothiazide may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methyclothiazide.
Levomilnacipran
Levomilnacipran may increase the hyponatremic activities of Methyclothiazide.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Methyclothiazide.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Methyclothiazide.
Licorice Allergenic Extract
Licorice may increase the hypokalemic activities of Methyclothiazide.
Limonene, (+)-
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with (4R)-limonene.
Linagliptin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methyclothiazide.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methyclothiazide.
Lisinopril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Lisinopril.
Lithium
Methyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Lithium Cation
Methyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Methyclothiazide.
Lornoxicam
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.
Losartan
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.
Loteprednol
Loteprednol may increase the hypokalemic activities of Methyclothiazide.
Loxoprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Loxoprofen.
Magnesium Salicylate
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.
Mannitol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.
Masoprocol
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Masoprocol.
Mecamylamine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.
Meclofenamate
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.
Meclofenamic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.
Medrysone
Medrysone may increase the hypokalemic activities of Methyclothiazide.
Mefenamic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mefenamic acid.
Meloxicam
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Methyclothiazide.
Mephobarbital
Methylphenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Methyclothiazide.
Mesalamine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.
Metaproterenol
Orciprenaline may increase the hypokalemic activities of Methyclothiazide.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Methyclothiazide.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methyclothiazide.
Methantheline
The serum concentration of Methyclothiazide can be increased when it is combined with Methantheline.
Methazolamide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.
Methixene
The serum concentration of Methyclothiazide can be increased when it is combined with Metixene.
Methohexital
Methohexital may increase the orthostatic hypotensive activities of Methyclothiazide.
Methscopolamine
The serum concentration of Methyclothiazide can be increased when it is combined with Methscopolamine.
Methscopolamine Bromide
The serum concentration of Methyclothiazide can be increased when it is combined with Methylscopolamine bromide.
Methyldopa
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.
Methylprednisolone
Methylprednisolone may increase the hypokalemic activities of Methyclothiazide.
Metipranolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.
Metolazone
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.
Metoprolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metoprolol.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Methyclothiazide.
Milnacipran
Milnacipran may increase the hyponatremic activities of Methyclothiazide.
Minoxidil
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Minoxidil.
Moexipril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Moexipril.
Mometasone
Mometasone may increase the hypokalemic activities of Methyclothiazide.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.
Moxonidine
The risk or severity of adverse effects can be increased when Moxonidine is combined with Methyclothiazide.
MYCOPHENOLATE
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.
Mycophenolate Mofetil
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Methyclothiazide.
Nabumetone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nabumetone.
Nadolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.
Naftifine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naftifine.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Methyclothiazide.
Naproxen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide.
Nebivolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.
Nefazodone
Nefazodone may increase the hyponatremic activities of Methyclothiazide.
Nepafenac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nepafenac.
Nesiritide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nesiritide.
Nicardipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Methyclothiazide.
Nifedipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nifedipine.
Niflumic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Niflumic Acid.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Methyclothiazide.
Nimesulide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.
Nimodipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.
Nisoldipine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Methyclothiazide.
Nitroglycerin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroglycerin.
Nitroprusside
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroprusside.
Norepinephrine
Norepinephrine may increase the hypokalemic activities of Methyclothiazide.
Normethadone
The risk or severity of adverse effects can be increased when Normethadone is combined with Methyclothiazide.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Methyclothiazide.
Octotropine Methylbromide
The serum concentration of Methyclothiazide can be increased when it is combined with Anisotropine Methylbromide.
Octylonium
The serum concentration of Methyclothiazide can be increased when it is combined with Otilonium.
Oenothera biennis seed extract
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Evening primrose oil.
Olmesartan
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan.
Olodaterol
Olodaterol may increase the hypokalemic activities of Methyclothiazide.
Olopatadine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.
Olsalazine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.
Opium
The risk or severity of adverse effects can be increased when Opium is combined with Methyclothiazide.
Orphenadrine
The serum concentration of Methyclothiazide can be increased when it is combined with Orphenadrine.
Ouabain
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ouabain.
Ovine Digoxin Immune Fab
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin Immune Fab (Ovine).
Oxaprozin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.
Oxcarbazepine
The risk or severity of hyponatremia can be increased when Methyclothiazide is combined with Oxcarbazepine.
Oxitropium
The serum concentration of Methyclothiazide can be increased when it is combined with Oxitropium.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Methyclothiazide.
Oxybutynin
The serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Methyclothiazide.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Methyclothiazide.
Oxyphenbutazone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.
Oxyphenonium
The serum concentration of Methyclothiazide can be increased when it is combined with Oxyphenonium.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyclothiazide.
Pancuronium
The serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.
Pancuronium Bromide
The serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.
Papaverine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.
Paramethasone
Paramethasone may increase the hypokalemic activities of Methyclothiazide.
Parecoxib
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.
Paricalcitol
The risk or severity of hyperkalemia can be increased when Paricalcitol is combined with Methyclothiazide.
Paroxetine
Paroxetine may increase the hyponatremic activities of Methyclothiazide.
Parthenolide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parthenolide.
Penbutolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.
Pentobarbital
Pentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Perindopril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Perindopril.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Methyclothiazide.
Phenformin
The therapeutic efficacy of Phenformin can be decreased when used in combination with Methyclothiazide.
Phenobarbital
Phenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Methyclothiazide.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Methyclothiazide.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Phentolamine is combined with Methyclothiazide.
Phenylbutazone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.
Phenylpropanolamine
Phenylpropanolamine may increase the hypokalemic activities of Methyclothiazide.
Pimecrolimus
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pimecrolimus.
Pindolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pindolol.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Methyclothiazide.
Pipecuronium
The serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.
Pirbuterol
Pirbuterol may increase the hypokalemic activities of Methyclothiazide.
Pirenzepine
The serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.
Pirfenidone
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.
Pirinitramide
The risk or severity of adverse effects can be increased when Piritramide is combined with Methyclothiazide.
Piroxicam
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Methyclothiazide.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Methyclothiazide.
Prasterone
Prasterone may increase the hypokalemic activities of Methyclothiazide.
Prazosin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Prazosin.
Prednicarbate
Prednicarbate may increase the hypokalemic activities of Methyclothiazide.
Prednisolone
Prednisolone may increase the hypokalemic activities of Methyclothiazide.
Prednisone
Prednisone may increase the hypokalemic activities of Methyclothiazide.
Pregnenolone
Pregnenolone may increase the hypokalemic activities of Methyclothiazide.
Primidone
Primidone may increase the orthostatic hypotensive activities of Methyclothiazide.
Procaterol
Procaterol may increase the hypokalemic activities of Methyclothiazide.
Procyclidine
The serum concentration of Methyclothiazide can be increased when it is combined with Procyclidine.
Profenamine
The serum concentration of Methyclothiazide can be increased when it is combined with Ethopropazine.
Propantheline
The serum concentration of Methyclothiazide can be increased when it is combined with Propantheline.
Propantheline Bromide
The serum concentration of Methyclothiazide can be increased when it is combined with Propantheline.
Propiverine
The serum concentration of Methyclothiazide can be increased when it is combined with Propiverine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Methyclothiazide.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methyclothiazide.
Propranolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propranolol.
Proscillaridin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Proscillaridin.
Quetiapine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.
Quinapril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Quinapril.
Quinidine
The serum concentration of Methyclothiazide can be increased when it is combined with Quinidine.
Ramipril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Ramipril.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Methyclothiazide.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methyclothiazide.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.
Rescinnamine
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Rescinnamine.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Methyclothiazide.
Resveratrol
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.
Rimexolone
Rimexolone may increase the hypokalemic activities of Methyclothiazide.
Riociguat
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Riociguat.
Risperidone
Methyclothiazide may increase the hypotensive activities of Risperidone.
Ritodrine
Ritodrine may increase the hypokalemic activities of Methyclothiazide.
Rofecoxib
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Rofecoxib.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Methyclothiazide.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methyclothiazide.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Methyclothiazide.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Methyclothiazide.
Salicylamide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.
Salicylic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylic acid.
Salmeterol
Salmeterol may increase the hypokalemic activities of Methyclothiazide.
Salsalate
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.
Saxagliptin
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.
Saxagliptin Anhydrous
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide.
Scopolamine
The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.
Scopolamine Hydrobromide
The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.
Secobarbital
Secobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Methyclothiazide.
Serratiopeptidase
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Serrapeptase.
Sertraline
Sertraline may increase the hyponatremic activities of Methyclothiazide.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyclothiazide.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.
Sitagliptin Phosphate
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide.
Sodium Phosphate
Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate.
Sodium Phosphate, Monobasic
Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate.
Solifenacin
The serum concentration of Methyclothiazide can be increased when it is combined with Solifenacin.
Sotalol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.
Spirapril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.
Sulfasalazine
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.
Sulpiride
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sulpiride.
Suprofen
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.
Tacalcitol
The risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Methyclothiazide.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Methyclothiazide.
Tapentadol
The risk or severity of adverse effects can be increased when Tapentadol is combined with Methyclothiazide.
Telmisartan
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.
Tenoxicam
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tenoxicam.
Terazosin
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.
Terbutaline
Terbutaline may increase the hypokalemic activities of Methyclothiazide.
Terbutaline Sulfate
Terbutaline may increase the hypokalemic activities of Methyclothiazide.
Teriflunomide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Methyclothiazide.
Thiamylal
Thiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.
Thiopental
Thiopental may increase the orthostatic hypotensive activities of Methyclothiazide.
Thiopental Sodium
Thiopental may increase the orthostatic hypotensive activities of Methyclothiazide.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Methyclothiazide.
Tiaprofenic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tiaprofenic acid.
Timolol
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Timolol.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Timolol.
Tiotropium
The serum concentration of Methyclothiazide can be increased when it is combined with Tiotropium.
Tixocortol
Tixocortol may increase the hypokalemic activities of Methyclothiazide.
Tizanidine
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.
Tolazoline
The risk or severity of adverse effects can be increased when Tolazoline is combined with Methyclothiazide.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Methyclothiazide.
Tolfenamic Acid
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.
Tolmetin
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.
Tolterodine
The serum concentration of Methyclothiazide can be increased when it is combined with Tolterodine.
Toremifene
Methyclothiazide may increase the hypercalcemic activities of Toremifene.
Torsemide
The risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.
Trandolapril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Trandolapril.
Tranilast
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyclothiazide.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Methyclothiazide.
Triamcinolone
Triamcinolone may increase the hypokalemic activities of Methyclothiazide.
Triamterene
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.
Tricalcium Phosphate
Methyclothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.
Trihexyphenidyl
The serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.
Trihexyphenidyl Hydrochloride
The serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl.
Trimethaphan
The serum concentration of Methyclothiazide can be increased when it is combined with Trimethaphan.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Methyclothiazide.
Tropicamide
The serum concentration of Methyclothiazide can be increased when it is combined with Tropicamide.
Trospium
The serum concentration of Methyclothiazide can be increased when it is combined with Trospium.
Tubocurarine
The serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.
Umeclidinium
The serum concentration of Methyclothiazide can be increased when it is combined with Umeclidinium.
Valdecoxib
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.
Vecuronium
The serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.
Venlafaxine
Venlafaxine may increase the hyponatremic activities of Methyclothiazide.
Verapamil
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.
Vilanterol
Vilanterol may increase the hypokalemic activities of Methyclothiazide.
Vildagliptin
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methyclothiazide.
Vitamin D
The risk or severity of hyperkalemia can be increased when Vitamin D is combined with Methyclothiazide.
Zileuton
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zileuton.
Zofenopril
The risk or severity of hypotension can be increased when Methyclothiazide is combined with Zofenopril.
Zomepirac
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.
